Overview

Pharmacokinetic Study of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin

Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter pharmacokinetic study of HD od PD patients receiving erythropoietin. Patients were administered 100mg of iron sucrose undiluted by slow IV push over 5 minutes. Patients underwent serial blood draws and were subsequently followed for 7 days for safety endpoints.
Phase:
Phase 4
Details
Lead Sponsor:
American Regent, Inc.
Luitpold Pharmaceuticals
Treatments:
Ferric Compounds
Ferric Oxide, Saccharated
Iron